CARM Pharmaceuticals Faces Challenges Amid Stock Plunge CARM Pharmaceuticals has hit a 52-week low, with its stock dropping to $0.35, marking an 84.38% decline over the past year. Despite strong liquidity and more cash than debt, the company faces regulatory hurdles and increased competition. Analysts have mixed views, with price targets ranging from $1 to $12.12